Advent of hs-Troponins in ED Didn t Lead to Cascades of Testing medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
May 4, 2021
But no increases in overall use of resources
The use of high-sensitivity cardiac troponin-T (hs-cTnT) assays significantly increased the number of diagnoses of myocardial injury and myocardial infarction (MI), especially in women and those with type 2 MI; however, apart from angiography, it did not increase the use of overall resources. In patients without increases in cTnT, researchers documented more ED discharges and less cardiac testing.
In the first study of its kind, Olatunde Ola, MD, MPH, of the Mayo Clinic Health System, La Crosse, Wisconsin, and colleagues assessed the transition from a contemporary cardiac troponin T (cTnT) assay that used an overall 99
April 23, 2021
The Valve Academic Research Consortium (VARC) has updated their standardized definitions of clinical endpoints for transcatheter and surgical aortic valve clinical trials, including bioprosthetic valve dysfunction and failure, structural complications, conduction disturbances, and repeat hospitalizations, among others.
Published this week in the
European Heart Journal and the
Journal of the American College of Cardiology, the VARC-3 update was adopted given the “rapid evolution of the field,” including the emergence of new complications, expanding clinical indications, and novel therapy strategies, according to the writing committee.
As aortic valve research moves into younger patients, as well as those with less advanced aortic stenosis, future trials be they head-to-head comparisons of TAVI devices, TAVI versus surgery, or even TAVI or surgery versus medical therapy will need standardized definitions for capturing appropriate endpoints, the authors stre
April 23, 2021
The hunt continues for a simple lab test that might help clinicians expeditiously sort out which type of MI is afflicting patients who present to the emergency department with chest pain, so as to streamline care. The latest effort, which evaluated 17 novel CV biomarkers, failed to uncover any that offered much in the way of help.
None was significantly better at discriminating between type 1 and type 2 MI when compared with troponins measured using high-sensitivity assays, which themselves have only modest diagnostic value for this purpose, Thomas Nestelberger, MD (Vancouver General Hospital, Canada, and University Hospital Basel, Switzerland), and colleagues report in a study published online April 21, 2021, ahead of print in